ロード中...
Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?
BACKGROUND: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the bes...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
International Scientific Literature, Inc.
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3962326/ https://ncbi.nlm.nih.gov/pubmed/24632679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.889945 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|